ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 160 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,367,694 | +273.5% | 211,969 | +615.6% | 0.01% | +200.0% |
| Q2 2023 | $633,932 | -57.6% | 29,623 | -7.8% | 0.00% | -60.0% |
| Q4 2022 | $1,493,943 | +103.0% | 32,114 | +126.3% | 0.01% | +66.7% |
| Q3 2022 | $736,000 | +14.6% | 14,192 | +4.4% | 0.00% | +50.0% |
| Q2 2022 | $642,000 | -89.6% | 13,591 | -83.6% | 0.00% | -84.6% |
| Q4 2021 | $6,183,000 | +68.0% | 82,682 | +27.6% | 0.01% | +62.5% |
| Q3 2021 | $3,680,000 | +27.3% | 64,778 | -1.4% | 0.01% | +14.3% |
| Q2 2021 | $2,890,000 | -9.0% | 65,677 | +2.0% | 0.01% | -12.5% |
| Q1 2021 | $3,177,000 | +15.7% | 64,410 | -1.3% | 0.01% | 0.0% |
| Q4 2020 | $2,747,000 | +27.8% | 65,239 | +38.9% | 0.01% | 0.0% |
| Q3 2020 | $2,150,000 | -35.8% | 46,954 | -29.7% | 0.01% | -52.9% |
| Q2 2020 | $3,351,000 | -36.6% | 66,748 | -35.0% | 0.02% | -60.5% |
| Q1 2020 | $5,284,000 | -36.5% | 102,734 | -23.8% | 0.04% | +72.0% |
| Q4 2019 | $8,325,000 | +102.1% | 134,755 | +96.6% | 0.02% | +78.6% |
| Q3 2019 | $4,119,000 | -17.3% | 68,557 | +16.1% | 0.01% | -17.6% |
| Q2 2019 | $4,982,000 | +86.9% | 59,046 | +111.7% | 0.02% | +88.9% |
| Q1 2019 | $2,665,000 | -38.2% | 27,896 | -54.2% | 0.01% | -47.1% |
| Q4 2018 | $4,311,000 | +114.5% | 60,867 | +158.8% | 0.02% | +240.0% |
| Q3 2018 | $2,010,000 | -80.8% | 23,515 | -73.9% | 0.01% | -83.9% |
| Q2 2018 | $10,451,000 | +137.9% | 90,172 | +66.1% | 0.03% | +106.7% |
| Q1 2018 | $4,393,000 | +27.0% | 54,295 | -7.9% | 0.02% | +36.4% |
| Q4 2017 | $3,459,000 | +429.7% | 58,955 | +322.5% | 0.01% | +450.0% |
| Q3 2017 | $653,000 | -60.4% | 13,953 | -69.6% | 0.00% | -66.7% |
| Q2 2017 | $1,651,000 | +206.9% | 45,876 | +162.6% | 0.01% | +200.0% |
| Q1 2017 | $538,000 | -83.1% | 17,473 | -81.6% | 0.00% | -83.3% |
| Q4 2016 | $3,189,000 | +78.0% | 95,196 | +41.3% | 0.01% | +100.0% |
| Q3 2016 | $1,792,000 | +84.7% | 67,348 | +174.8% | 0.01% | +50.0% |
| Q3 2014 | $970,000 | +36.4% | 24,512 | +48.6% | 0.00% | +33.3% |
| Q2 2014 | $711,000 | -47.0% | 16,499 | -66.4% | 0.00% | -57.1% |
| Q4 2013 | $1,341,000 | – | 49,148 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |